Insider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $25.74, for a total transaction of $45,045.00. Following the sale, the insider now directly owns 1,737 shares in the company, valued at $44,710.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Scott Bizily also recently made the following trade(s):

• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $31.78, for a total transaction of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $35.04, for a total transaction of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $31.27, for a total transaction of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.67, for a total transaction of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.50, for a total transaction of $171,710.00.

4D Molecular Therapeutics Stock Down 2.1 %

FDMT stock traded down $0.52 during mid-day trading on Thursday, hitting $24.78. 417,554 shares of the company were exchanged, compared to its average volume of 1,078,209. The firm has a market capitalization of $1.27 billion, a P/E ratio of -9.32 and a beta of 2.87. The business has a fifty day simple moving average of $28.97 and a 200-day simple moving average of $20.13. 4D Molecular Therapeutics, Inc. has a 12-month low of $9.44 and a 12-month high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The company had revenue of ($0.02) million for the quarter, compared to analysts’ expectations of $4.67 million. 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.03 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bfsg LLC purchased a new position in 4D Molecular Therapeutics during the fourth quarter worth about $30,000. International Assets Investment Management LLC purchased a new position in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $36,000. US Bancorp DE boosted its stake in shares of 4D Molecular Therapeutics by 580.7% in the fourth quarter. US Bancorp DE now owns 1,797 shares of the company’s stock valued at $36,000 after purchasing an additional 1,533 shares during the period. Lazard Asset Management LLC boosted its stake in shares of 4D Molecular Therapeutics by 44.2% in the second quarter. Lazard Asset Management LLC now owns 2,190 shares of the company’s stock valued at $38,000 after purchasing an additional 671 shares during the period. Finally, Ensign Peak Advisors Inc boosted its stake in shares of 4D Molecular Therapeutics by 167.9% in the third quarter. Ensign Peak Advisors Inc now owns 7,180 shares of the company’s stock valued at $58,000 after purchasing an additional 4,500 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on FDMT. The Goldman Sachs Group reiterated a “buy” rating and issued a $81.00 target price on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. Barclays started coverage on shares of 4D Molecular Therapeutics in a research report on Monday. They issued an “overweight” rating for the company. Jefferies Financial Group raised their price objective on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Royal Bank of Canada raised their price objective on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, March 1st. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $44.22.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.